WilmerHale Reps Apellis Pharmaceuticals in $60 Million Series E Financing

WilmerHale Reps Apellis Pharmaceuticals in $60 Million Series E Financing

Firm News

On August 10, 2017, Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, announced the closing of a $60 million Series E preferred stock financing.

WilmerHale represented Apellis in this transaction, with a team led by Stuart Falber and included Mhairi Immermann and Alicia Lee.

Read Apellis' press release

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.